Class Action Lawsuit Filed Against Sarepta Therapeutics Over Elevidys Treatment Concern

Investor Alert: Class Action Lawsuit Against Sarepta Therapeutics

On July 7, 2025, the Pomerantz Law Firm publicly announced a class action lawsuit against Sarepta Therapeutics, Inc. (NASDAQ: SRPT). This legal action arises amidst serious allegations against the company, including potential securities fraud and other unlawful business practices. Investors who have incurred losses from this entity are urged to engage with Pomerantz LLP to ensure their voice is heard in the proceedings.

Key Information

Investors with interests in Sarepta Therapeutics, particularly those who purchased shares during the defined class period, need to act promptly. The deadline for filing as a Lead Plaintiff is August 25, 2025. Interested parties can reach out to Pomerantz representatives directly via phone or email for additional guidance and support. It is recommended that investors provide their contact information and specifics about their share acquisitions to streamline the process.

Background of the Case

The lawsuit is largely prompted by Sarepta Therapeutics' handling of data surrounding its drug, ELEVIDYS, which is designed to treat Duchenne muscular dystrophy. On March 18, 2025, Sarepta announced the tragic death of a patient following treatment with ELEVIDYS due to acute liver failure. This news significantly impacted the company's stock, resulting in a drop of 27.44%, closing at $73.54 per share.

In the following weeks, unexpected regulatory scrutiny intensified when EU authorities mandated a meeting with the data monitoring committee to review the aforementioned death. Consequently, Sarepta halted patient recruitment for some clinical studies, sending its stock down by a further 7.13% to $54.43 per share by April 4, 2025.

As distressing reports regarding patient fatalities continued, another disclosure on June 15, 2025, confirmed a second death attributed to the same treatment. This revelation caused an astonishing stock price decrease of 42.12%, plummeting to $20.94 the subsequent trading day. Following accusations of safety concerns, FDA measures investigated the risk associated with ELEVIDYS, further destabilizing investor confidence.

Pomerantz Law Firm's Role

Pomerantz LLP has a distinguished history in fighting for investor rights, further complemented by its esteemed reputation in class action litigation. The firm is dedicated to ensuring that justice is served for those misled by corporate malpractice or fraudulent activity. They have recovered multi-million dollar settlements in numerous class actions in their illustrious 85-year history.

Action Steps for Investors

Investors affected by Sarepta’s recent troubles are advised to assess their options swiftly. Communication with Pomerantz LLP is highly encouraged, especially if one has experienced financial downturns related to the company’s disclosures. Investors not only deserve truthful representations but also have the right to seek redress for any possible securities violations.

To learn more about joining the class action or to obtain a copy of the complaint, visit Pomerantz Law Firm’s website.

As the deadline approaches, swift action will ensure that affected investors can stand united in their claim for compensation in this concerning situation surrounding Sarepta Therapeutics.